Commercial-Scale mRNA / LNP CDMOs
mRNA and lipid nanoparticle (LNP) manufacturing scaled rapidly after COVID-19 vaccines and now supports therapeutics across rare disease, oncology, and infectious disease. The platform pairs IVT mRNA synthesis with LNP formulation — two distinct capability sets.
Choosing an mRNA/LNP CDMO depends on IVT scale, template strategy (linearized plasmid vs PCR), LNP formulation and microfluidics, and cold-chain handling. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 19 NAI (no action), 16 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: Germany (34), United States (33), UNITED KINGDOM (21), Denmark (15), Italy (15).
Last updated 2026-06-23. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
PC
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
|
91.5 | 100.0 | 4 insp · 17 GMP | — | 363 programs |
| 2 |
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
|
88.0 | 100.0 | 0 insp · 3 GMP | — | 0 programs |
| 3 |
AE
Aldevron
Fargo, ND
|
85.3 | 100.0 | 1 insp · 0 GMP | — | 0 programs |
| 4 |
BNT
BioNTech (Mfg Services)
Mainz, DE · Marburg, DE
|
84.8 | 100.0 | 0 insp · 8 GMP | — | 24 programs |
| 5 |
FD
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
|
83.5 | 100.0 | 0 insp · 18 GMP | 0 programs | |
| 6 |
CD
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
|
82.5 | 99.7 | 2 insp · 9 GMP | — | 0 programs |
| 7 |
MR
Moderna (Contract Mfg)
Norwood, MA
|
81.8 | 100.0 | 2 insp · 3 GMP | — | 10 programs |
| 8 |
MK
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
|
81.8 | 98.6 | 2 insp · 2 GMP | — | 22 programs |
| 9 |
WK
Wacker Biotech
Jena, DE · Amsterdam, NL · San Diego, CA
|
81.6 | 100.0 | 0 insp · 13 GMP | — | 0 programs |
| 10 |
DH
Danaher (CGT Portfolio)
Washington, DC
|
81.5 | — | — | — | 0 programs |
| 11 |
EK
Evonik Health Care
Birmingham, AL · Vancouver, BC
|
81.5 | 99.8 | 2 insp · 2 GMP | — | 0 programs |
| 12 |
ND
Nitto Denko Avecia
Milford, MA
|
80.3 | 100.0 | 2 insp · 0 GMP | — | 0 programs |
| 13 |
KE
Kaneka Eurogentec
Seraing, BE
|
80.3 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 14 |
CRA
Curia (RNA/Advanced)
Albany, NY · Albuquerque, NM
|
79.4 | 99.9 | 2 insp · 16 GMP | — | 0 programs |
| 15 |
Lonza
Basel, Switzerland
|
78.2 | 95.1 | 2 insp · 8 GMP | — | 1 programs |
| 16 |
CC
CCRM
Toronto, ON
|
78.1 | 100.0 | 5 insp · 0 GMP | — | 0 programs |
| 17 |
PBI
ProBio
Taipei, TW
|
78.1 | 100.0 | 0 insp · 9 GMP | — | 0 programs |
| 18 |
Catalent
Somerset, NJ (now operating under Novo Holdings, HQ effectively Bagsværd, Denmark)
|
76.5 | 79.3 | 10 insp · 32 GMP | — | 0 programs |
| 19 |
CVC
CureVac (CDMO Services)
Tubingen, DE
|
75.3 | 100.0 | 0 insp · 7 GMP | — | 4 programs |
| 20 |
CA
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
|
75.1 | 79.3 | 1 insp · 0 GMP | Available | 0 programs |
| 21 |
NR
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
|
73.4 | 97.7 | 1 insp · 0 GMP | Available | 9 programs |